Inferra AIResearch Tools

Inferra AI / Company / DGX

Quest Diagnostics

DGX · Health Care

Last earnings Oct 22, 2026

Key results

Revenuequarter

$2.82 billion

revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

EPSquarter

13.1%

revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Growthquarter

up 8.5%

revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Revenues grew 13.1%, including 6.8% organic growth, driven by broad-based adoption of our clinical innovations, contributions from acquisitions, and growth in our consumer channel as we build our presence as the preferred lab engine inside top health and wellness brands.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Selling, general, and administrativequarter

$1 million

Selling, general and administrative $ $ 1 $ $ 2

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

AI analysis

Q3 2025 · reported Oct 21, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q3 2025
$2.82B
EX-99 · Oct 21, 2025
Selling, general, and administrative · Q3 2025
$1M
EX-99 · Oct 21, 2025

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Oct 21, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$2.82 billion——
EPS13.1%——
Growthup 8.5%——
Selling, general, and administrative$1 million——

EX-99 · Oct 21, 2025

Guidance · company-stated

Direction: Raised

Revenue$2.82 billion

“htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2025 Financial Results Raises Guidance for Full Year 2025 Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66 and adjusted diluted EPS is expected to be between $9.76 and $9.84 SECAUCUS, N.”

Revenue

“Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows Updated Guidance Prior Guidance Low High Low High Net revenues $10.96 billion $11.00 billion $10.80 billion $10.92 billion Net revenues increase 11.0% 11.4% 9.4% 10.6% Reported diluted EPS $8.58 $8.66 $8.60 $8.80 Adjusted diluted EPS $9.76 $9.84 $9.63 $9.83 Cash provided by operations Approximately $1.8 billion Approximately $1.55 billion Capital expenditures Approximately $500 million Approximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term reported refers to measures under accounting principles generally accepted in the United States ( GAAP ).”

EPS

“The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS Low High Diluted EPS $ 8.58 $ 8.66 Restructuring and integration charges (a) 0.30 0.30 Amortization expense (b) 1.02 1.02 Other charges (c) 0.39 0.39 Other gains (d) (0.36) (0.36) Gains and losses on investments (e) (0.01) (0.01) ETB (0.16) (0.16) Adjusted diluted EPS $ 9.76 $ 9.84 (a) Represents estimated pre-tax charges of $45 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.”

Company outlook — Raised

“Given our strong performance year-to-date, we are again raising our full year 2025 guidance.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Net revenue11.0%

Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows Updated Guidance Prior Guidance Low High Low High Net revenues $10.96 billion $11.00 billion $10.80 billion $10.92 billion Net revenues increase 11.0% 11.4% 9.4% 10.6% Reported diluted EPS $8.58 $8.66 $8.60 $8.80 Adjusted diluted EPS $9.76 $9.84 $9.63 $9.83 Cash provided by operations Approximately $1.8 billion Approximately $1.55 billion Capital expenditures Approximately $500 million Approximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term reported refers to measures under accounting principles generally accepted in the United States ( GAAP ).

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

We also announced an agreement with Corewell Health to create a major lab services joint venture serving the state of Michigan

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2025 Financial Results Raises Guidance for Full Year 2025 Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66 and adjusted diluted EPS is expected to be between $9.76 and $9.84 SECAUCUS, N.”

Revenue: “Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows Updated Guidance Prior Guidance Low High Low High Net revenues $10.96 billion $11.00 billion $10.80 billion $10.92 billion Net revenues increase 11.0% 11.4% 9.4% 10.6% Reported diluted EPS $8.58 $8.66 $8.60 $8.80 Adjusted diluted EPS $9.76 $9.84 $9.63 $9.83 Cash provided by operations Approximately $1.8 billion Approximately $1.55 billion Capital expenditures Approximately $500 million Approximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term reported refers to measures under accounting principles generally accepted in the United States ( GAAP ).”

EPS: “The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS Low High Diluted EPS $ 8.58 $ 8.66 Restructuring and integration charges (a) 0.30 0.30 Amortization expense (b) 1.02 1.02 Other charges (c) 0.39 0.39 Other gains (d) (0.36) (0.36) Gains and losses on investments (e) (0.01) (0.01) ETB (0.16) (0.16) Adjusted diluted EPS $ 9.76 $ 9.84 (a) Represents estimated pre-tax charges of $45 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.”

Revenue — Raised (“Raises”)
“htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2025 Financial Results Raises Guidance for Full Year 2025 Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ( EPS ) of $2.16, up 8.5% from 2024 and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66 and adjusted diluted EPS is expected to be between $9.76 and $9.84 SECAUCUS, N.”

Company outlook — Raised (“raising”)
“Given our strong performance year-to-date, we are again raising our full year 2025 guidance.”

Revenue — Raised (“increase”)
“Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows Updated Guidance Prior Guidance Low High Low High Net revenues $10.96 billion $11.00 billion $10.80 billion $10.92 billion Net revenues increase 11.0% 11.4% 9.4% 10.6% Reported diluted EPS $8.58 $8.66 $8.60 $8.80 Adjusted diluted EPS $9.76 $9.84 $9.63 $9.83 Cash provided by operations Approximately $1.8 billion Approximately $1.55 billion Capital expenditures Approximately $500 million Approximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term reported refers to measures under accounting principles generally accepted in the United States ( GAAP ).”

EPS — Lowered (“reductions”)
“The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS Low High Diluted EPS $ 8.58 $ 8.66 Restructuring and integration charges (a) 0.30 0.30 Amortization expense (b) 1.02 1.02 Other charges (c) 0.39 0.39 Other gains (d) (0.36) (0.36) Gains and losses on investments (e) (0.01) (0.01) ETB (0.16) (0.16) Adjusted diluted EPS $ 9.76 $ 9.84 (a) Represents estimated pre-tax charges of $45 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows Updated Guidance Prior Guidance Low High Low High Net revenues $10.96 billion $11.00 billion $10.80 billion $10.92 billion Net revenues increase 11.0% 11.4% 9.4% 10.6% Reported diluted EPS $8.58 $8.66 $8.60 $8.80 Adjusted diluted EPS $9.76 $9.84 $9.63 $9.83 Cash provided by operations Approximately $1.8 billion Approximately $1.55 billion Capital expenditures Approximately $500 million Approximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term reported refers to measures under accounting principles generally accepted in the United States ( GAAP ).

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

9 3) For both the three and nine months ended September 30, 2025, we repurchased 0.9 million shares of our common stock for $150 million.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

As of September 30, 2025, $0.7 billion remained available under our share repurchase authorization.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Earnings Per Share The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan ( ELTIP ) and its Amended and Restated Non-Employee Director Long-Term Incentive Plan ( DLTIP ), as well as the dilutive effect of accelerated share repurchase agreements, if applicable.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Strategy & priorities

We delivered another quarter of robust top- and bottom-line growth, underscoring strong demand for our clinical solutions and diligent execution of our strategy, said Jim Davis, Chairman, CEO and President.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Announced a collaboration with Epic to be the technology partner for Project Nova, a multi-year initiative to streamline systems and improve experiences for patients and providers, regardless of the electronic health record system they use.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

The term adjusted refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ( ETB ) associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

The Company's pre-tax restructuring charges for the three and nine months ended September 30, 2025 included $ 6 million and $ 18 million, respectively, of employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

The Company's investment portfolio primarily includes equity investments comprised mostly of strategic holdings in companies concentrated in the life sciences and healthcare industries.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Risks & headwinds

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Such estimate is subject to the risks and uncertainties discussed in the Forward Looking Statements section above.

SEC original ↗Quest Diagnostics — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Certain Legal Matters The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

In 2020, two putative class action lawsuits were filed in the U.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident.

SEC original ↗Quest Diagnostics — 10-Q Quarterly report10-QOct 23, 2026

Documents

Earnings deck slides

0 decks with slide view

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Quest Diagnostics — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

68 documents

Earnings releases

24 documents

Presentations

9 documents

Transcripts

0 documents

No transcripts for Quest Diagnostics are held in this edition of the library.

Mentioned by

7 companies

Other tracked companies whose held documents mention Quest Diagnostics by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.